Manufacturing plant-made monoclonal antibodies for research or therapeutic applications.
Methods Enzymol
; 660: 239-263, 2021.
Article
in English
| MEDLINE | ID: covidwho-1283203
ABSTRACT
Monoclonal antibodies (mAbs) hold great promise for treating diseases ranging from cancer to infectious disease. Manufacture of mAbs is challenging, expensive, and time-consuming using mammalian systems. We describe detailed methods used by Kentucky BioProcessing (KBP), a subsidiary of British American Tobacco, for producing high quality mAbs in a Nicotiana benthamiana host. Using this process, mAbs that meet GMP standards can be produced in as little as 10 days. Guidance for using individual plants, as well as detailed methods for large-scale production, are described. These procedures enable flexible, robust, and consistent production of research and therapeutic mAbs.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antineoplastic Agents, Immunological
/
Antibodies, Monoclonal
Limits:
Animals
Language:
English
Journal:
Methods Enzymol
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS